This clinical trial is focused on studying a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). CIDP is a rare neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. The study is testing a new treatment called riliprubart, which is given as a solution for injection. The purpose of the study is to evaluate the effects and safety of riliprubart in people with CIDP for whom the usual treatments do not work.
Participants in the study will receive either riliprubart or a placebo, which is a substance with no active medication. The study will be conducted over a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their health and the effects of the treatment. The study aims to assess how well riliprubart works in improving the symptoms of CIDP and its long-term effects on the condition.
Throughout the study, participants will be closely monitored for any changes in their condition and any side effects they may experience. The study will use various measures to evaluate the effectiveness of riliprubart, including changes in disability scores and grip strength. The goal is to determine if riliprubart can provide a meaningful improvement for people with CIDP who have not responded to other treatments.
Belgium 
Bulgaria 
Czechia 
Denmark 
France 
Germany 
Greece 
Italy 
Poland 
Portugal 
Spain 
Sweden 
The Netherlands 
